EP1207854A1 - Konservierte liposomen - Google Patents
Konservierte liposomenInfo
- Publication number
- EP1207854A1 EP1207854A1 EP00959298A EP00959298A EP1207854A1 EP 1207854 A1 EP1207854 A1 EP 1207854A1 EP 00959298 A EP00959298 A EP 00959298A EP 00959298 A EP00959298 A EP 00959298A EP 1207854 A1 EP1207854 A1 EP 1207854A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- amount
- preserved
- cosmetic composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to the preservation of liposomal preparations against microbial contamination. More particularly, the present invention relates to a cosmetic liposomal preparations containing active ingredients which have previously been difficult to preserve, such as magnesium ascorbyl phosphate.
- Liposomes are spherical vesicles composed of lipid bilayers. Active ingredients inside the liposomes can be delivered to the skin by topical application of the liposomes.
- a general reference for the application of liposomes to cosmetics is Hayward, J.A. and Smith, W.P. Potential Applications of Liposomes in Cosmetic Science, in Cosmetic and Toiletries, 105:47-54, 1990.
- U.S. Pat. No. 5,585,109 to Hayward et al. teaches the cosmetic delivery of un-neutralized salicylic acid by a liposome formulation including a preservative.
- Liposome formulations are typically difficult to preserve against microbiological contamination.
- An 8-week challenge study is considered a standard measure of preservative efficacy within the cosmetic industry. All percentages given in the specification are percent by weight of the total composition weight, unless otherwise noted.
- a preserved cosmetic composition comprising: a) a vesicle-forming amount of lipids known to form, either alone or in combination, unilamellar vesicles; b) a cosmetic-effective amount of an active ingredient; c) a preservative-effective amount of a combination of sorbic acid and salicylic acid or water-soluble salts thereof; d) a base in an amount which provides a pH of about 5 to about 6 to the composition; and e) water.
- the cosmetic liposomes of the invention can optionally contain other ingredients conventionally employed in cosmetic products.
- ingredients include, but are not limited to, perfumes, colorants such as staining dyes and pigments, humectants, anti- dandruff agents, anti-acne agents, germicides, sunscreens, emollients, vitamins, sterols and other lipids.
- Preferred lipids include the synthetic or natural phospholipids, phosphatidylthanolamines, phosphatidylserines, cereamides, cerebrosides, phophatidylglycerides and non-ionic surfactants.
- Particularly preferred lipids are natural phospholipids such as soya lecithin, in an amount of 0.5 to 10%.
- Most preferred are natural phospholipids which have been substantially purified to increase the phosphatidylcholine content.
- Preferred active ingredients include any ingredient known for cosmetic use through topical application.
- active ingredients for use in the cosmetic liposomes of the invention include, but are not limited to, vitamins, herbal extracts, enzymes, growth factors, anti-dandruff agents, anti-acne agents, germicides and sterols.
- a "cosmetic-effective amount" of an active ingredient is that amount which is required in a liposome preparation for the active ingredient to have a discernible cosmetic effect upon topical application.
- a "preservative-effective amount" of a combination of sorbic acid and salicylic acid or water-soluble salts thereof is at least 0.1% of sorbic acid or a water-soluble salt of sorbic acid in combination with at least 0.1% of salicylic acid or a water-soluble salt of salicylic acid.
- sorbic acid is present in an amount from 0.1% to 5%
- salicylic acid or its water-soluble salt are present in an amount from 0.1% to 10%.
- the base used may be either organic or inorganic.
- a liposome composition of the cosmetic active ingredient magnesium ascorbyl phosphate is preserved by the addition of sorbic acid and salicylic acid.
- Previously known preservative systems were unsuccessful in preserving liposome compositions of magnesium ascorbyl phosphate.
- Magnesium ascorbyl phosphate functions to deliver a stabilized form of Vitamin C (ascorbic acid) to the skin.
- the stabilized Vitamin C functions as an antioxidant, skin tightener and pigment promoter.
- EXAMPLE 1 Mg Ascorbyl Phosphate Liposomes Preserved with 0.2% Salicylic Acid and 0.2% Sorbic Acid
- the sorbic acid and the salicylic acid were dissolved in water.
- the pH was then adjusted to a pH of 5.5 using the base.
- the active ingredient, Mg ascorbyl phosphate, was then added.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfulidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer (Horiba Instruments, Inc., Irvine, California).
- Mg ascorbyl phosphate liposomes were also prepared using two prior art preservatives, Phenonip (Nipa-Hardwicke, Inc., Wilmington, Deleware), and the combination of Dowicil (Dow Chemical USA, Midland, Michigan), methyl paraben and propyl paraben.
- Phenonip Napa-Hardwicke, Inc., Wilmington, Deleware
- Dowicil Dowicil
- the Phenonip was dissolved in water.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfiilidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer.
- the Dowicil 200, methyl paraben and propyl paraben were dissolved in water.
- the active ingredient, Mg ascorbyl phosphate, was then added.
- the lecithin is added under agitation, and the mixture is processed by high shear homogenization or microfiilidization until a particle size of between 100 nm and 300 nm is reached.
- the particle size was monitored by a Horiba LA-90 particle size analyzer.
- Comparative Example 2 were each inoculated with standardized cultures to provide a final concentration of 5.0 x 10 5 gram positive bacteria per gram, 5.0 x 10 5 gram negative bacteria per gram, 5.0 x 10 5 yeast per gram and 5.0 x 10 4 mold spores per gram.
- the inoculum was distributed uniformly throughout the preserved samples in a manner which minimized aeration. The samples were then stored at room temperature for the duration of the eight week study.
- each sample was taken one week after the first inoculation and every week thereafter until the eighth week.
- Each portion was diluted and plated on a series of petri dishes containing media which were selective for each of gram positive bacteria, gram negative bacteria, yeast and mold.
- the series of plates were then incubated. Following incubation, the number of colonies on the plates was determined using a colony counter and used to calculate the number of organisms per gram for each class of gram positive bacteria, gram negative bacteria, yeast and mold.
- the salicylic acid/sorbic acid of Example 1 provided a stable preservative for the liposomes, even in the face of repeated challenges with bacteria, yeast, and mold spores.
- the phenonip preserved and Dowicil 200/methyl paraben/propyl paraben preserved liposomes failed to provide adequate protection from even one challenge.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US390411 | 1982-06-22 | ||
US39041199A | 1999-09-03 | 1999-09-03 | |
PCT/US2000/022985 WO2001017507A1 (en) | 1999-09-03 | 2000-08-22 | Preserved liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1207854A1 true EP1207854A1 (de) | 2002-05-29 |
Family
ID=23542376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00959298A Withdrawn EP1207854A1 (de) | 1999-09-03 | 2000-08-22 | Konservierte liposomen |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1207854A1 (de) |
JP (1) | JP2003535030A (de) |
WO (1) | WO2001017507A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006124300A (ja) * | 2004-10-27 | 2006-05-18 | Takasago Internatl Corp | ベシクル調製物 |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4643939A (en) * | 1986-03-04 | 1987-02-17 | Shiseido Company Ltd. | Oil absorbing cosmetic tissue |
US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
FR2687314A1 (fr) * | 1992-02-18 | 1993-08-20 | Oreal | Dispersion de vesicules lipidiques, composition cosmetique et/ou pharmaceutique la contenant et procede de preparation de ladite dispersion. |
SG65599A1 (en) * | 1993-03-24 | 1999-06-22 | Collaborative Lab Inc | Cosmetic delivery system for salicylic acid and process for preparation of same |
-
2000
- 2000-08-22 EP EP00959298A patent/EP1207854A1/de not_active Withdrawn
- 2000-08-22 JP JP2001521298A patent/JP2003535030A/ja active Pending
- 2000-08-22 WO PCT/US2000/022985 patent/WO2001017507A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0117507A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001017507A1 (en) | 2001-03-15 |
JP2003535030A (ja) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1242095B1 (de) | Antimikrobielle zusammensetzungen sowie verfahren zu ihrer verwendung | |
AU2005201276B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
JP2958774B2 (ja) | アンホテリシンbリポソームの改良調整法 | |
EP0153364B1 (de) | Verbesserung der antimikrobiellen wirkung durch verbindung eines gemisches von antimikrobiellen agenzien in lipidbläschen | |
EP1386905B1 (de) | Reduziertes coenzym q enthaltende, stabile lösung | |
US8232320B2 (en) | Antimicrobial nanoemulsion compositions and methods | |
EP1041978A1 (de) | Verfahren zur inaktivierung von bakterien mit einbegriff von bakteriensporen | |
US20110091556A1 (en) | Antimicrobial compositions and methods of use | |
US20020045667A1 (en) | Non-toxic antimicrobial compositions and methods of use | |
US20110070306A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
KR101474577B1 (ko) | 미토콘드리아 기능의 향상을 위한 카디오리핀 포함 리포좀 | |
AU2002350587A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
JPH06279230A (ja) | サリチル酸賦与のための化粧品組成物とその製法 | |
CN101557803B (zh) | 用于改善线粒体功能的含有心磷脂的脂质体 | |
JPS63126820A (ja) | 外皮用リポソ−ム製剤 | |
EP1035837B1 (de) | Lipidzusammensetzungen und deren verwendung | |
EP1207854A1 (de) | Konservierte liposomen | |
WO2005030172A1 (en) | Antimicrobial nanoemulsion compositions and methods | |
EP1360958A2 (de) | Liposomenformulierung mit clobetasol propionate | |
US6936273B2 (en) | Liposomal analgesic formulation and use | |
KR102189174B1 (ko) | 산업용 항균제 조성물 | |
BRPI0903009B1 (pt) | Vesículas lipídicas de carotenoides, composição, processo de preparação de vesículas lipídicas de carotenoides e uso de vesículas lipídicas de carotenoides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB |
|
18W | Application withdrawn |
Effective date: 20040414 |